Type 2 Diabetes, Psoriasis
Conditions
Keywords
type 2 diabetes, psoriasis, exenatide, liraglutide
Brief summary
The aim of the study is to evaluate after 4 to 6 months the effects of a GLP-1 analog treatment on psoriatic skin lesions in patients with type 2 diabetes.
Detailed description
The objective of this study is to analyse short and medium-term efficacy on clinical, immunological and histopathological parameters of a GLP-1 receptor agonist on moderate to severe psoriasis plaques in a group of patients with type 2 diabetes.
Interventions
DRUGGLP-1 analog
GLP-1 analog treatment
Sponsors
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetic patients treated with oral anti-hyperglycaemic agents and/or insulin and presenting stable psoriasis plaques for at least one year, which failed to respond to previous systemic and/or topical treatments.
Exclusion criteria
* Type 1 diabetes * Secondary diabetes * Liver, renal or pancreatic disease * Previous treatment with GLP-1 agonist or DPP-4 inhibitors agents
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of PASI score | 4 to 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evolution of immunological data | 4 to 6 months | cytokines and T cells |
| Evolution of histopathological data | 4 to 6 months | thickness, dermis infiltrate in skin plaques and in control areas |
| Evolution of BMI (body mass index) | 4 to 6 months | number of patients with weight loss |
| Evolution of routine laboratory measures | 4 to 6 months | number of participants with biological adverse effects (pancreatitis enzymes) |
| Evolution of BMI | 4 to 6 months | weight |
| Evolution of glycaemic control | 4 to 6 months | HbA1c |
Countries
Belgium
Outcome results
None listed